Video

Educated Patient Multiple Myeloma Summit On-Demand: Nov. 21, 2020

Author(s):

CURE Media Group

View the full CURE®Educated Patient® Multiple Myeloma Summit here!

View the full CURE®Educated Patient® Multiple Myeloma Summit here!

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of two doctors and text.
Imiage of two doctors with text.
Image of two doctors and text.
Image of patient and doctor.
Image of two doctors with text.
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Image of thumbnail.
Image of doctor.
Related Content
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
July 2nd 2025

FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma

Spencer Feldman
The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of ronald.
June 25th 2025

Traveling with Multiple Myeloma: A Journey of Adaptation and Hope

Ronald Chin
I share how traveling fueled my passion for life, how myeloma changed my journeys, and how new mobility options have opened doors to adventure and connection.
Cancer Horizons podcast logo
December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of two doctors with text.
June 20th 2025

Advancements Reshape Treatment for Non-Small Cell Lung Cancer

Ryan Scott
Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the REZILIENT-1 and NeoADAURA trials.
Image of breast.
June 19th 2025

Breaking Down the Impact of SERENA-6 for Some With Breast Cancer

Ryan Scott
Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.